MX2018015463A - Co-cristales de benzoato de litio y sus usos. - Google Patents

Co-cristales de benzoato de litio y sus usos.

Info

Publication number
MX2018015463A
MX2018015463A MX2018015463A MX2018015463A MX2018015463A MX 2018015463 A MX2018015463 A MX 2018015463A MX 2018015463 A MX2018015463 A MX 2018015463A MX 2018015463 A MX2018015463 A MX 2018015463A MX 2018015463 A MX2018015463 A MX 2018015463A
Authority
MX
Mexico
Prior art keywords
crystals
disorders
lithium benzoate
formula
compound
Prior art date
Application number
MX2018015463A
Other languages
English (en)
Spanish (es)
Inventor
Emil Tsai Guochuan
Cheng Wang Ching-
Lan HSIEH Tien-
Chun Lo Yuan-
Original Assignee
Syneurx Int Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syneurx Int Taiwan Corp filed Critical Syneurx Int Taiwan Corp
Publication of MX2018015463A publication Critical patent/MX2018015463A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C07C57/10—Sorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C07C57/44—Cinnamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018015463A 2016-06-13 2017-06-13 Co-cristales de benzoato de litio y sus usos. MX2018015463A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349582P 2016-06-13 2016-06-13
PCT/CN2017/088044 WO2017215592A1 (en) 2016-06-13 2017-06-13 Co-crystals of lithium benzoate and uses thereof

Publications (1)

Publication Number Publication Date
MX2018015463A true MX2018015463A (es) 2019-05-27

Family

ID=60663075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015463A MX2018015463A (es) 2016-06-13 2017-06-13 Co-cristales de benzoato de litio y sus usos.

Country Status (12)

Country Link
US (2) US10815184B2 (enExample)
EP (1) EP3468946B1 (enExample)
JP (1) JP6958923B2 (enExample)
KR (2) KR102488927B1 (enExample)
CN (1) CN109563024B (enExample)
CA (1) CA3027300C (enExample)
ES (1) ES3074457T3 (enExample)
IL (1) IL263486B (enExample)
MX (1) MX2018015463A (enExample)
RU (2) RU2765625C2 (enExample)
TW (1) TWI736635B (enExample)
WO (1) WO2017215592A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017215593A1 (en) * 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
EP0572560B1 (en) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US6362226B2 (en) 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
ATE401313T1 (de) 2000-08-14 2008-08-15 Teva Pharma Herstellung von risperidon
CA2433866A1 (en) 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
JP2006526635A (ja) 2003-06-02 2006-11-24 サマリタン,ファーマスーティカルス,インク. 血清中コルチゾール量を調節する方法および組成物
ZA200605384B (en) 2003-12-29 2007-10-31 Sepracor Inc Benzo[D]isoxazol-3-OL DAAO inhibitors
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
ATE454140T1 (de) 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
BRPI0509592A (pt) 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
EP1765379A4 (en) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2505808A1 (en) * 2005-05-02 2006-11-02 Julie Danielle Globus Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
US20130338199A1 (en) * 2008-07-11 2013-12-19 Uday Saxena Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
US8541435B2 (en) * 2008-07-11 2013-09-24 Uday Saxena Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
JP2010106001A (ja) * 2008-10-31 2010-05-13 Theravalues Corp Ppar活性化剤
MX353752B (es) 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
PT3650439T (pt) * 2010-07-23 2021-03-03 Gruenenthal Gmbh Sais ou cocristais de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol
US10130708B2 (en) * 2011-03-24 2018-11-20 University Of South Florida Lithium cocrystal compositions
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
US9120766B2 (en) * 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
LT2986618T (lt) * 2013-04-19 2022-04-11 University Of South Florida Organinio anijono ličio joniniai kokristaliniai junginiai ir kompozicijos
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
PT3079675T (pt) * 2013-12-13 2020-03-05 Conaris Res Institute Ag Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal
DE212014000063U1 (de) * 2014-03-24 2015-10-12 China Medical University Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung
CN103992320A (zh) * 2014-05-26 2014-08-20 南京工业大学 一种混悬结晶制备药物共晶的方法
EP4026545A1 (en) * 2014-11-19 2022-07-13 Rush University Medical Center Compositions and methods for treating lysosomal disorders
RU2582962C1 (ru) 2014-12-23 2016-04-27 Ольга Алексеевна Громова Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
WO2017215593A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof

Also Published As

Publication number Publication date
CN109563024B (zh) 2023-06-06
US10815184B2 (en) 2020-10-27
CN109563024A (zh) 2019-04-02
RU2018146423A (ru) 2020-07-14
CA3027300A1 (en) 2017-12-21
EP3468946B1 (en) 2026-05-13
TWI736635B (zh) 2021-08-21
US20210107856A1 (en) 2021-04-15
EP3468946A4 (en) 2020-02-12
KR102338171B1 (ko) 2021-12-09
RU2022101542A (ru) 2022-02-03
IL263486A (en) 2019-01-31
JP2019518757A (ja) 2019-07-04
RU2765625C2 (ru) 2022-02-01
CA3027300C (en) 2023-08-08
EP3468946A1 (en) 2019-04-17
US11739046B2 (en) 2023-08-29
US20190177261A1 (en) 2019-06-13
TW201811321A (zh) 2018-04-01
EP3468946C0 (en) 2026-05-13
KR20190017939A (ko) 2019-02-20
KR20210142769A (ko) 2021-11-25
IL263486B (en) 2021-08-31
ES3074457T3 (en) 2026-07-21
KR102488927B1 (ko) 2023-01-13
RU2018146423A3 (enExample) 2020-10-06
WO2017215592A1 (en) 2017-12-21
JP6958923B2 (ja) 2021-11-02

Similar Documents

Publication Publication Date Title
CL2018002794A1 (es) Compuestos bicíclicos
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CL2016002573A1 (es) Compuesto de ciclopropanamina y sus usos.
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
DOP2016000242A (es) Uso de compuestos heterocíclicos para controlar nematodos
DOP2017000066A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2015012736A (es) 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.
CU20170116A7 (es) Compuestos cíclicos terapéuticos como inmunomoduladores
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112016028773A2 (pt) processos para preparação de compostos antivirais
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
UY36716A (es) Moduladores de receptores nucleares
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
CO2017000337A2 (es) Derivados de bis(aril)catecol como herbicidas
CR20170247A (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY36348A (es) Derivados de benzotiofenilo sustituidos como agonistas del gpr40 para el tratamiento de la diabetes tipo ii
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR101036A1 (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
MX388612B (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
DOP2016000211A (es) Pirazinas moduladoras de gpr6
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.